Overview

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics of neratinib and to assess the safety and tolerability of neratinib in healthy subjects and subjects with chronic liver disease.
Phase:
Phase 1
Details
Lead Sponsor:
Puma Biotechnology, Inc.